Cardiac Arrest, Out-Of-Hospital

7
Pipeline Programs
2
Companies
2
Clinical Trials
1 recruiting
6
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
7
Early DiscoveryClinical DevelopmentMarket

On Market (6)

Approved therapies currently available

U
ADRENACLICKApproved
epinephrine
Unknown Company
alpha-Adrenergic Agonist [EPC]intramuscular, subcutaneous2003
Pfizer
ADRENALINApproved
epinephrine
Pfizer
alpha-Adrenergic Agonist [EPC]intramuscular, intravenous, subcutaneous2013
U
AUVI-QApproved
epinephrine
Unknown Company
alpha-Adrenergic Agonist [EPC]intramuscular, subcutaneous2012
Pfizer
PRIMATENE MISTApproved
epinephrine
Pfizer
inhalation1967
U
SYMJEPIApproved
epinephrine
Unknown Company
intramuscular, subcutaneous2017
U
TWINJECTApproved
epinephrine
Unknown Company
alpha-Adrenergic Agonist [EPC]intramuscular, subcutaneous2003

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Pfizer
PfizerNEW YORK, NY
1 program
1
EpinephrinePhase 41 trial
Active Trials
NCT03826524Recruiting3,790Est. Dec 2028
Zoll
ZollCA - San Jose
1 program
AED 3 with Uni-padzN/A1 trial
Active Trials
NCT05013333Active Not Recruiting38Est. Feb 2029

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
PfizerEpinephrine
ZollAED 3 with Uni-padz

Clinical Trials (2)

Total enrollment: 3,828 patients across 2 trials

NCT03826524PfizerEpinephrine

Epinephrine Dose: Optimal Versus Standard Evaluation Trial

Start: May 2023Est. completion: Dec 20283,790 patients
Phase 4Recruiting
NCT05013333ZollAED 3 with Uni-padz

AED 3 Post-Approval Study

Start: Mar 2021Est. completion: Feb 202938 patients
N/AActive Not Recruiting

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 actively recruiting trials targeting 3,828 patients
2 companies competing in this space